Introduction to olaratumab (LARTRUVO) and review of its marketing history

Olaratumab, trade name: LARTRUVO, is a humanized monoclonal antibody drug specifically used to treat advanced soft tissue sarcoma (STS). It exerts anti-tumor effects by targeting and inhibiting platelet-derived growth factor receptor α (PDGFR-α). The drug was developed by Eli Lilly and Company (Eli Lilly), an American pharmaceutical company. As a new targeted therapy, it provides a new treatment option for patients with soft tissue sarcoma that cannot be controlled by traditional treatments.

LARTRUVO inhibits the proliferation and angiogenesis of tumor cells by binding to PDGFR-α receptor. PDGF is an important factor for tumor cell growth and tumor microvessel formation. By blocking this pathway, LARTRUVO can slow the growth of tumors and restrict their blood supply, thereby achieving the effect of treating tumors. In addition, LARTRUVO can also enhance the immune system's ability to recognize and eliminate tumor cells, thereby further improving the therapeutic effect.

LARTRUVOis mainly used to treat advanced soft tissue sarcoma (STS), especially those patients who are ineffective or resistant to conventional treatments (such as chemotherapy, radiotherapy). Soft tissue sarcoma is a type of malignant tumor originating from soft tissues of the body (such as muscle, fat, nerve tissue, etc.). Patients with advanced stages have lower survival rates and often require new treatment options.

LARTRUVOUsually used in combination with the chemotherapy drug docetaxel (docetaxel), which can significantly improve the therapeutic effect. Clinical studies have shown that LARTRUVO used in combination with chemotherapy can significantly prolong patient survival and improve progression-free survival (PFS). Furthermore, it was shown to be relatively well tolerated and the overall safety profile was well managed, although side effects included nausea, fatigue, leukopenia, etc.

The development process of LARTRUVO began in the mid-2000s. Eli Lilly and Company made important progress in its targeted therapy research on PDGFR-α receptors. 2016Year10Month, LARTRUVOhas been approved by the U.S. Food and Drug Administration (FDA)\ as a targeted therapy for the treatment of advanced soft tissue sarcoma. FDA approved LARTRUVO based on its significant efficacy and relatively low side effects shown in clinical trials.

The approval of LARTRUVO brings new light to the treatment of soft tissue sarcoma, especially in a patient population for which traditional chemotherapy has limited effectiveness. Clinical data shows that LARTRUVO combined with chemotherapy is of great significance in improving patient survival rate and prolonging progression-free survival. After FDA approval, LARTRUVO quickly entered the global market and became an important drug in the treatment of soft tissue sarcoma.

Reference materials:https://www.drugs.com/cdi/olaratumab.html